Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. by Jit, Mark
- Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jvalThemed Section: VaccinesInforming Global Cost-Effectiveness Thresholds Using Country Investment
Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018
Mark Jit, BSc, PhD, MPH1098-30
open acA B S T R A C T
Objectives: Cost-effectiveness analysis can guide decision making about health interventions, but the appropriate cost-
effectiveness threshold to use is unclear in most countries. The World Health Organization (WHO) recommends
vaccinating girls 9 to 14 years against human papillomavirus (HPV), but over half the world’s countries have not
introduced it. This study aimed to investigate whether country-level decisions about HPV vaccine introduction are
consistent with a particular cost-effectiveness threshold, and to estimate what that threshold may be.
Methods: The cost-effectiveness of vaccinating 12-year-old girls was estimated in 179 countries using the Papillomavirus
Rapid Interface for Modelling and Economics (PRIME) model, together with vaccine price data from World Health
Organization’s Market Information for Access to Vaccines database. In each year from 2006 to 2018, countries were
categorized based on (1) whether they had introduced HPV vaccination, and (2) whether the incremental cost-
effectiveness ratio for HPV vaccine introduction fell below a certain cost-effectiveness threshold.
Results: A cost-effectiveness threshold of 60% to 65% of GDP per capita has the best ability to discriminate countries that
introduced vaccination, with a diagnostic odds ratio of about 7. For low-income countries the optimal threshold was
lower, at 30% to 40% of GDP per capita.
Conclusions: A cost-effectiveness threshold has some ability to discriminate between HPV vaccine introducer and non-
introducer countries, although the average threshold is below the widely used threshold of 1 GDP per capita. These
results help explain the current pattern of HPV vaccine use globally. They also inform the extent to which cost-
effectiveness thresholds proposed in the literature reflect countries’ actual investment decisions.
Keywords: cost-effectiveness analysis, cost-effectiveness thresholds, human papillomavirus vaccination, incremental cost-
effectiveness ratio.
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Cost-effectiveness analysis has been promoted as a tool to help
countries make good decisions about allocation of healthcare
spending. Its use has greatly expanded in the last 2 decades,
particularly in low- and middle-income countries.1
In its most common form to inform a decision about whether
or not to make a particular health investment, the cost per quality-
adjusted life-year gained or disability-adjusted life-year (DALY)
averted for the investment is calculated incrementally to the next
best alternative (eg, the status quo). This incremental cost-
effectiveness ratio (ICER) is then compared to a cost-
effectiveness threshold (CET). If the ICER is above the CET, then
the investment is generally deemed not cost-effective, although
other criteria like equity and acceptability are usually also rec-
ommended to be considered alongside cost-effectiveness.215 - see front matter Copyright ª 2020, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/bAnalysts are hindered from this procedure, because only a few
countries have publicly available data about the appropriate CET
to use.3 In the absence of such information, one widely used CET is
to spend a maximum of 1 to 3 times gross domestic product (GDP)
per capita to avert a DALY.4 This CET was originally proposed by
the World Health Organization (WHO)’s Commission on Macro-
economics and Health using human capital arguments around the
market value created by averting a DALY. Nevertheless, this CET
has been widely criticized for failing to account for healthcare
budget limits and the opportunity cost of healthcare spending in
most countries.4-6 Indeed, the WHO itself has cautioned against
use of such a CET for country-level decision making.2 A previous
review found that many countries had not introduced human
papillomavirus (HPV) or rotavirus vaccines despite their being
found to be cost-effective according to this CET.5Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
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appropriate CET is to consider the marginal productivity of current
healthcare expenditure, because this represents the health gains
thatmay be displaced by new investments. This approachwas used
to suggest that aCETof around £13000 (below50%of England’sGDP
per capita) per quality-adjusted life-year gained should be used in
England.7 This analysis required information on healthcare
spending and disease-specific mortality across different program
categories, but such data are generally not available in most coun-
tries. Nevertheless, simpler analyses using either changes in
healthcare expenditure overall8 or extrapolation of the English
analysis to other countries9 suggest that CETs for low- and middle-
income countries should be set well below GDP per capita.
The link between these econometric analyses on national in-
dicators and decisions about individual technologies still has to be
established. Examining individual decisions at the country level to
see what kind of CET they are consistent with (if any) would be
useful to inform discussions around appropriate CETs. In partic-
ular, understanding decisions made by countries in different in-
come categories and regions could bring understanding about the
determinants of health opportunity costs in different countries.
Nevertheless, such analyses would require information about both
price and cost-effectiveness of the technology, which are rarely
available across all countries.
One notable exception is HPV vaccination. The HPV vaccine
was first licensed in the United States in 2006. Vaccine prices are
tiered at levels that would theoretically allow countries at all in-
come levels to purchase it. Prices that countries pay to procure the
vaccine have been collected by the WHO since 2013 based on
anonymous country reporting.10 There is now strong evidence
about the vaccine’s efficacy,11 health impact,12 and economic
benefits, including a global cost-effectiveness evaluation that
published ICERs for 179 countries.13 Vaccinating 9- to 14-year-old
girls is recommended by the WHO in all countries,14 and indeed
such a strategy forms an essential component of the WHO Di-
rector-General’s call for elimination of cervical cancer as a public
health problem globally. The WHO directives were partly driven
by cost-effectiveness considerations, based on a CET of 1 times
GDP per capita.15 HPV vaccination has been adopted in many low-,
middle-, and high-income countries, but over half the countries in
the world have yet to introduce it.16
The purpose of this article is to investigate whether country-
level decisions to introduce (or not introduce) HPV vaccination
are consistent with a CET, and to determine what that CET may be.Methods
Data Sources
Country categories
Historical classification of countries by income (low, upper mid-
dle, lower middle, and high) in 2006-2019 was obtained from the
World Bank (http://databank.worldbank.org/data/download/site-
content/OGHIST.xls). Categorization of countries into geographical
regions (Africa, Americas, EasternMediterranean, Europe, Southeast
Asia, and Western Pacific) was obtained from the WHO (https://
www.who.int/choice/demography/mortality_strata/en/).
Cost-effectiveness
The cost-effectiveness of HPV vaccine introduction for 12-year
old girls was estimated using the Papillomavirus Rapid Interface
for Modelling and Economics (PRIME). PRIME is a static model of
HPV vaccination that uses proportional impact to estimate the
cost-effectiveness of HPV vaccination before sexual debut. Cost-effectiveness results for all countries have been publicly avail-
able since 201413; the model itself is publicly available with a user-
friendly Excel interface (http://primetool.org). In this analysis, the
published results from 2014 were used (consistent with the online
tool), apart from updating vaccine prices to reflect new data and
assuming a 2-dose schedule was used instead of a 3-dose schedule
from 2015 following revised WHO recommendations.14 The cost-
effectiveness calculations account for costs of procuring and
delivering 2 to 3 doses, costs averted by vaccination from avoiding
cervical cancer treatment, and DALYs averted by vaccination from
preventing morbidity and mortality owing to cervical cancer.
Discounting at 3% for costs and benefits, a lifetime time horizon
and healthcare perspective were used.
Year of vaccine introduction
The nonprofit organization PATH tracks HPV vaccine intro-
duction status and year of introduction for all countries16 (data on
file from D. Scott LaMontagne, personal communication). The first
year of a program being initiated was regarded as the year of
introduction, regardless of whether it was a national, subnational,
pilot, or demonstration program. In a sensitivity analysis, only
actual national long-term introductions were considered.
Cost of vaccine purchase
TheWHO’s Market Information for Access to Vaccines database
contains information on vaccine prices paid by reporting countries
from 2013 to 2018.10 The exact country names are anonymized
owing to commercial sensitivities; however, information is avail-
able about country characteristics including World Bank income
category and WHO region. All data on HPV vaccine procurement
prices were extracted from the database. When these data were
disaggregated by year of procurement, World Bank income cate-
gory, WHO region, and vaccine brand (Gardasil or Cervarix), no
consistent pattern was observable (see Appendix 1 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.07.
012). Hence, instead of extrapolating a linear trend to years
before 2013, the average procurement cost for each World Bank
income category and WHO region was assigned to all countries
within those categories regardless of year (see Table 1). In cate-
gories where there were no data, the average across the World
Bank income category was used instead.
Cost of vaccine delivery
Vaccine delivery was assumed to cost $5, $15, and $25 per fully
immunized girl for low-income, middle-income, and high-income
countries, respectively, based on previous analyses.13
Analysis
The estimated ICER of HPV vaccine introduction was calculated
for 179 countries. Different CETs were then generated, ranging
from 0% to 100% (in 1% increments) of each country’s GDP per
capita. In each year from 2006 to 2018, countries were categorized
based on (1) whether they had already introduced HPV vaccina-
tion, and (2) whether the ICER of HPV vaccine introduction fell at
or below each CET. For each year and CET, countries were then
placed into 4 categories to determine the diagnostic ability of that
CET in predicting country introduction status: (1) true positive
(TP): vaccine introduced, ICER # CET; (2) false positive (FP): vac-
cine not yet introduced, ICER # CET; (3) true negative (TN): vac-
cine not yet introduced, ICER . CET; and (4) false negative (FN):
vaccine introduced, ICER . CET.
For each year and CET value, 2 measures of the accuracy of the
CET were then calculated: (1) diagnostic accuracy, (TP 1 TN) /
(TP 1 FP 1 FP 1 TN), and (2) diagnostic odds ratio, (TP / FP) / (FN /
Table 1. Average price paid per HPV vaccine dose (in USD) by countries in WHO’s MI4A database from 2013-2018.
WHO region World Bank country income classification
High Upper-middle Lower-middle Low
Africa 27.87 15.25 4.60 4.59
Americas 10.75 9.35 7.18 No data
Eastern Mediterranean No data No data No data No data
Europe 48.86 50.04 4.75 No data
Southeast Asia No data 9.59 5.73 No data
Western Pacific 56.31 20.17 8.31 No data
HPV indicates human papillomavirus; MI4A, Market Information for Access to Vaccines; WHO, World Health Organization.
THEMED SECTION: VACCINES 63TN). The diagnostic odds ratio captures the ability of the CET to
discriminate between true positives (countries that introduced
HPV vaccination) and true negatives (countries that did not
introduce HPV vaccination).
Graphs of these measures by CET value were plotted by fitting
cubic splines through the results using the R function smooth.s-
pline. All analyses were conducted in R version 3.5.2.Results
Figure 1 shows the number of countries that had introduced
HPV vaccination each year from 2006 to 2018. The number of full
introductions in high- and middle-income countries increased
steadily each year. Pilot introductions in low- and middle-income
countries began increasing after 2008, but these proceeded to full
introductions mainly in middle-income countries. The number of
pilot introductions in these increased until 2016, after which it
plateaued.Figure 1. Number of countries each year with full or pilot introduct
HPV, human papillomavirus.Countries having introduced HPV vaccination had on average
higher ICERs than the non-introducers until 2012. After 2012,
ICERs for introducers dropped below that in non-introducers as
more middle-income countries started to introduce vaccination. In
2019, vaccine introducers had a median ICER of 15.21% of GDP per
capita (interquartile range 8.34-26.94) compared to 21.48% (9.97-
52.02) for non-introducers (see Appendix 2 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.07.012 for
further details).
Figure 2 shows the diagnostic odds ratios for different CET
values; corresponding diagnostic accuracy values are shown in
Appendix 3 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2020.07.012. Before 2011, any CET has poor diag-
nostic ability since few countries had introduced HPV vaccination
regardless of how cost-effective it was. Over time, an appropri-
ately chosen CET performed increasingly well in discriminating
vaccine introducers and non-introducers, reaching an odds ratio of
around 7 by 2018 at a CET of 60% to 65% of GDP per capita. At that
CET, diagnostic accuracy could reach around 70%. Nevertheless, in
low-income countries, a CET of only 30% to 40% of GDP per capitaions of HPV vaccination by income group.
Figure 2. Diagnostic odds ratio of different cost-effectiveness thresholds in predicting HPV vaccine introductions. Dots indicate actual
model results while lines are cubic splines fitted to the dots.
GDP, gross domestic product; HPV, human papillomavirus.
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introductions only still gave an optimum CET at 60% to 65% of GDP
per capita, but the diagnostic odds ratio and accuracy were lower.Conclusions
This study investigated the extent to which cost-effectiveness
at different CETs influenced HPV vaccine introduction decisions
by linking the cost-effectiveness of introducing HPV vaccination
for 12-year-old girls with country vaccine introduction status.
Results suggest that a CET of 60% to 65% of GDP per capita has
moderate ability to discriminate between introducing and non-
introducing countries, particularly in the later years of theperiod from 2006 to 2018. This optimum CET had a diagnostic
odds ratio of about 7, meaning that the odds of the ICER being
below the CET in introducers to non-introducers is about 7 times
the odds of being above the CET.
The corresponding diagnostic accuracy of the optimum CET is
around 65%, so about a third of countries made vaccine introduc-
tion decisions (either positive or negative) that were not predicted
by the CET. Together, the diagnostic accuracy and odds ratio suggest
that cost-effectiveness had an important influence in introduction
decisions, but was not the only consideration. This is consistent
with advice fromWHO2 and others17 that cost-effectiveness should
be considered as one input in a multi-criteria decision framework
alongside other evidence-based criteria such as affordability,
sustainability, equity, and acceptability. Also, the ability of the
THEMED SECTION: VACCINES 65optimum CET to predict country decisions in most cases does not
imply that cost-effectiveness was formally considered in decision
making. Even if it was, the assumptions and input parameters used
in a country’s own evaluationmay have differed from those used in
this analysis. It could instead indicate that key inputs to the ICER
such as high cervical cancer burden compared with the cost of
vaccination were influential in the decision. Nevertheless, the
pattern of country decisions does imply that the level of disease
burden and vaccine costs that was considered acceptable in each
country was on average consistent with a CET of 60% to 65% of GDP
per capita.
The most discriminatory CET was lower than the widely used
1-to-3-times-GDP-per-capita threshold, and for low-income
countries is similar to CETs suggested in econometric analyses of
healthcare spending.8,9 For middle-income countries it is gener-
ally higher than those in the econometric analyses. Nevertheless,
the ICERs estimated in this study may be underestimates, because
they rely on the simple PRIME model that ignores some vaccine
benefits such as herd effects (indirect protection of non-vaccinees)
and reduction in non-cervical disease (such as vulvar, vaginal,
penile, anal, and oropharyngeal cancer as well as anogenital
warts) to be able to generate results for almost all countries in the
world. Incorporating these benefits may bring the optimum CET to
close to the levels suggested in previous econometric analyses.
The analysis did not distinguish between sources of financing
that were internal or external to the country. Vaccine introduction
costs in low-income countries are heavily subsidized by Gavi, the
Vaccine Alliance. Hence from a country’s perspective the ICER of
vaccine introduction is even lower than suggested here, so the
optimum CET is also lower.
The analyses were conducted for each year from 2006 (when
HPV vaccination was first licensed in the United States) to 2019.
World Bank country income category and HPV vaccine introduc-
tion status were updated annually. Nevertheless, other parameters
(including GDP per capita, disease burden, vaccine costs, and
treatment costs) were not updated. This was for several reasons.
Firstly, data on treatment costs and cervical cancer burden are not
updated annually in most countries. For instance, vaccine price
data only started to be collected in 2014, while cervical cancer
burden estimates are only updated once every few years by the
International Agency for Research on Cancer.18 Furthermore,
countries themselves do not generally have access to any more
recent data than these on which to base introduction decisions, so
the decisions themselves are unlikely to reflect annually updated
parameters. Over time, it is likely that both GDP per capita (and
hence the absolute value of the corresponding CETs) and eco-
nomic impact of cervical cancer will increase for most countries,
but it is difficult to determine which of these trends is more
important without much better data.
HPV vaccination of young adolescent girls has been found to be
cost-effective in almost every country using a CET of 1 GDP per
capita.13 Yet most countries (particularly low-income countries)
have yet to introduce vaccination despite WHO recommendations
to do so. Obstacles to introduction include misunderstandings
about vaccine safety and efficacy, difficulty in delivering 2 doses of
the vaccine to adolescents, as well as competition with other
vaccines that are also recommended for introduction (such as
rotavirus and pneumococcal conjugate vaccines).19 Some of these
obstacles suggest that the health opportunity costs of HPV vaccine
introduction may be considerable in terms of the displaced hu-
man, planning, and financial resources in generating health. This is
consistent with our observation that the CET that best predicts
country introduction decisions is well below 1 GDP per capita,
particularly in low-income countries. This suggests that some
countries, particularly low-income countries, may need additionalfinancial and planning resources for HPV vaccine introductions to
become universal and the WHO’s goal of cervical cancer elimi-
nation to be achieved.Supplemental Material
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2020.07.012.Article and Author Information
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